Keywords: Biogen, Biovitrum, MophoSys, Galapagos, Factor VIII, Antibodies, Arthritis, Hemophilia

Biogen and Biovitrum update hemophilia agreement; MorphoSys and Galapagos expand accord

Article | 18 February 2010

Print This

US biotech firm Biogen Idec and Stockholm-based Biovitrum (now called Swedish Orphan Biovitrum since completion of the merger between the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in